Fortis C-DOC Centre of Excellence for Diabetes, Metabolic Diseases and Endocrinology, Chirag Enclave, Nehru Place, New Delhi, India.
Centre of Nutrition & Metabolic Research (C-NET), National Diabetes, Obesity and Cholesterol Foundation (N-DOC), SDA, New Delhi, India; Diabetes Foundation (India), SDA, New Delhi, India.
Clin Nutr ESPEN. 2021 Dec;46:519-526. doi: 10.1016/j.clnesp.2021.08.028. Epub 2021 Sep 6.
To determine the prevalence of hepatic steatosis and fibrosis in patients with T2DM from North India.
In this cross-sectional study, Asian Indian patients with T2DM (n,250) underwent liver ultrasonography (USG), Fibroscan for assessment of hepatic steatosis (Controlled Attenuation Parameter, CAP) and hepatic fibrosis (Kilopascals, kPa) respectively. Pearson's correlation analysis & logistic regression analysis for significant predictors of hepatic steatosis and fibrosis were done. The cut-off value of liver span was calculated by ROC-AUC analysis.
Grade 3 hepatic steatosis was seen in 213 T2DM patients (85.2%). It was higher in males than females and in those with high BMI values. Any degree of fibrosis and severe fibrosis were seen in 205 (62%) and 46 (18.4%) patients, respectively; these were higher in males, specifically in those with BMI >30 kg/m, and diabetes of a duration more than 5 years. BMI and SGPT were the significant predictors of hepatic steatosis. An increase of 1 unit of BMI above 23 kg/m led to 19.6 times increased risk of hepatic steatosis in T2DM patients aged 50 years and above. SGOT and GGTP were significant predictors of any degree of hepatic fibrosis. On ROC-AUC analysis, liver span cut-off values of ≥16.4 cms and ≥16.8 cm in males and females respectively, were predictive of hepatic fibrosis.
High prevalence of grade 3 hepatic steatosis and hepatic fibrosis needs increased vigilance and corrective lifestyle and pharmacological measures. Asian Indian patients with T2DM and BMI >30 kg/m, with duration of diabetes above 5 years & an ultrasound derived liver span ≥16.4 cms, should be further evaluated for hepatic fibrosis.
确定来自印度北部的 2 型糖尿病(T2DM)患者的肝脂肪变性和纤维化患病率。
在这项横断面研究中,对 250 例 T2DM 的亚裔印度患者进行了肝脏超声检查(USG)、Fibroscan 评估肝脂肪变性(受控衰减参数,CAP)和肝纤维化(千帕斯卡,kPa)。进行了 Pearson 相关性分析和逻辑回归分析,以确定肝脂肪变性和纤维化的显著预测因子。通过 ROC-AUC 分析计算肝跨度的截断值。
213 例 T2DM 患者出现 3 级肝脂肪变性(85.2%)。男性多于女性,BMI 值较高者肝脂肪变性程度较高。205 例(62%)和 46 例(18.4%)患者分别存在任何程度的纤维化和严重纤维化;男性、BMI>30kg/m2 且糖尿病病程超过 5 年的患者中这些情况更为常见。BMI 和 SGPT 是肝脂肪变性的显著预测因子。BMI 每增加 1 单位超过 23kg/m2,年龄在 50 岁及以上的 T2DM 患者发生肝脂肪变性的风险增加 19.6 倍。SGOT 和 GGTP 是任何程度肝纤维化的显著预测因子。在 ROC-AUC 分析中,男性和女性肝跨度截断值分别为≥16.4cms 和≥16.8cms,可预测肝纤维化。
高度的 3 级肝脂肪变性和纤维化患病率需要提高警惕并采取纠正生活方式和药物治疗措施。T2DM 伴 BMI>30kg/m2、糖尿病病程超过 5 年及超声衍生肝跨度≥16.4cms 的亚裔印度患者应进一步评估肝纤维化。